Cyclic SERPIN Peptide Derivatives for Stable LRP1 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing SERPIN-derived peptides face challenges with stability, bioavailability, and efficacy, particularly in targeting low-density lipoprotein receptor related protein-1 (LRP1), which affects their therapeutic potential in treating conditions associated with LRP1 mediation.
Innovation Solution
Development of SERPIN peptide derivatives with modifications such as cyclization, addition of polar heads and tails, amino acid substitutions, and conjugation to enhance LRP1 binding affinity, solubility, and oral bioavailability, including the use of disulfide bonds and linkers to form cyclic structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SERPIN-derived peptides are used to treat conditions associated with LRP1 mediation, then therapeutic efficacy is achieved, but stability and bioavailability are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (P1, P2, P3, P4, P5) of the SERPIN-derived peptide sequence. These substitutions alter the peptide's physicochemical properties including stability and bioavailability while maintaining LRP1 binding activity, thereby resolving the contradiction between therapeutic efficacy and stability
Solution Approach 2:
The patent creates composite peptide structures by combining the core SERPIN-derived sequence (VKFNKPFVFLM) with modified amino acid residues at specific positions. This composite approach allows the peptide to maintain its biological function while incorporating residues that improve stability and bioavailability properties
2Reliability
If SERPIN-derived peptides are used to treat conditions associated with LRP1 mediation, then therapeutic efficacy is achieved, but oral bioavailability is insufficient
Solution Approach 1:
The patent modifies peptide parameters by substituting amino acids at positions P2, P3, and P4 with residues that improve oral bioavailability (such as D-amino acids, cyclic structures, or residues with improved metabolic stability). These parameter changes enable the peptide to maintain therapeutic efficacy while enhancing its suitability for oral administration
3Reliability
If amino acid substitutions are made to improve LRP1 binding affinity, then binding activity is enhanced, but peptide stability may be compromised
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions at specific positions (P1-P5) of the peptide sequence rather than global modifications. Each substitution is carefully selected to enhance LRP1 binding affinity at the binding interface while minimizing impact on overall peptide stability through localized structural changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified SERPIN peptide derivatives exhibit improved LRP1 binding activity, solubility, and oral bioavailability, demonstrating enhanced anti-inflammatory effects and regenerative properties in models of neuroinflammation and allergic asthma.
Implementation Method 1
the SERPIN peptide derivative is cyclized by forming a disulfide bond between two Cys residues
Data Source
AI summary
Of the present technology are SERPIN peptide derivatives, methods of making the same, and uses of the same for treating various conditions associated with LRP1 mediation.